Home › Companies › Sutro Biopharma, Inc. › 2025-2026
At Sutro Biopharma, Inc.'s shareholder meeting held June 5, 2026, in the 2025-2026 proxy season, 75 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 207 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 99.8% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Sutro Biopharma, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 8, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Sutro Biopharma, Inc.’s Form 8-K, filed June 8, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 5, 2026: 5 items on Sutro Biopharma, Inc.’s Form 8-K, filed June 8, 2026: 5 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Sutro Biopharma, Inc. in the interactive database Compare manager voting policies
These tallies are Sutro Biopharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 8, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jane Chung | 11,355,214 | -- | -- | 3,596 | 2,540,863 | 99.9% | Not verified | — |
| Elect Director: Connie Matsui | 9,734,802 | -- | -- | 1,624,008 | 2,540,863 | 86% | Not verified | — |
| Elect Director: James Panek | 9,706,422 | -- | -- | 1,652,388 | 2,540,863 | 85% | Not verified | — |
| 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 13,893,289 | 501 | 5,883 | -- | -- | 99.9% | Not verified | — |
| 3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting | 11,329,946 | 22,412 | 6,452 | -- | 2,540,863 | 99.8% | Not verified | — |
This meeting is also recorded here as June 4, 2026; both records come from the same filing, so the date should be checked against it.
Source: Sutro Biopharma, Inc., Form 8-K, filed with the SEC on June 8, 2026 — read the filing on EDGAR.
Each item below shows how the 75 asset managers that disclosed a Sutro Biopharma, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Connie Matsui
Sutro Biopharma, Inc.’s own tally for this item (“Elect Director: Connie Matsui”): 9,734,802 for, 1,624,008 withheld, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,575,794 for, 8,988 withheld, 156 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 715,307 | 0 | 0 | 0 | For |
| Vanguard | 710,129 | 0 | 3 | 1,082 | For |
| Fidelity | 137,227 | 0 | 0 | 0 | For |
| Charles Schwab | 10,500 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 4,092 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 3,000 | Withhold |
| Equitable | 1,480 | 0 | 0 | 0 | For |
| BlackRock | 820 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 770 | Withhold |
| Invesco | 179 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 153 | 0 | Abstain |
| Northern Trust | 152 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 44 | Withhold |
Combines 4 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: James Panek
Sutro Biopharma, Inc.’s own tally for this item (“Elect Director: James Panek”): 9,706,422 for, 1,652,388 withheld, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,575,642 for, 9,140 withheld, 156 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 715,307 | 0 | 0 | 0 | For |
| Vanguard | 710,129 | 0 | 3 | 1,082 | For |
| Fidelity | 137,227 | 0 | 0 | 0 | For |
| Charles Schwab | 10,500 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 4,092 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 3,000 | Withhold |
| Equitable | 1,480 | 0 | 0 | 0 | For |
| BlackRock | 820 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 770 | Withhold |
| Invesco | 179 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 153 | 0 | Abstain |
| Northern Trust | 0 | 0 | 0 | 152 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 44 | Withhold |
Combines 4 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Jane Chung, RPh
Sutro Biopharma, Inc.’s own tally for this item (“Elect Director: Jane Chung”): 11,355,214 for, 3,596 withheld, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,584,937 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 715,307 | 0 | 0 | 0 | For |
| Vanguard | 711,213 | 0 | 0 | 0 | For |
| Fidelity | 137,227 | 0 | 0 | 0 | For |
| Charles Schwab | 10,500 | 0 | 0 | 0 | For |
| Goldman Sachs | 4,092 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 3,000 | 0 | 0 | 0 | For |
| Equitable | 1,480 | 0 | 0 | 0 | For |
| BlackRock | 820 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 770 | 0 | 0 | 0 | For |
| Invesco | 179 | 0 | 0 | 0 | For |
| John Hancock | 153 | 0 | 0 | 0 | For |
| Northern Trust | 152 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 44 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
Sutro Biopharma, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting”): 11,329,946 for, 22,412 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 715,307 | 0 | 0 | 0 | For |
| Vanguard | 711,213 | 0 | 0 | 0 | For |
| Fidelity | 137,227 | 0 | 0 | 0 | For |
| Charles Schwab | 10,500 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 4,092 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 3,000 | 0 | 0 | 0 | For |
| Equitable | 1,480 | 0 | 0 | 0 | For |
| BlackRock | 820 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 770 | 0 | 0 | 0 | For |
| Invesco | 0 | 179 | 0 | 0 | Against |
| John Hancock | 153 | 0 | 0 | 0 | For |
| Northern Trust | 152 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 44 | 0 | 0 | 0 | For |
Fund voting reports, all 13 managers: 1,580,666 for, 4,271 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BVF INC/IL | 1,251,788 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 1,046,966 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 714,753 | 0 | 0 | 0 | For |
| Point72 | 657,587 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 657,168 | 0 | 0 | 0 | For |
| Woodline Partners LP | 463,623 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 419,095 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 305,293 | 0 | 0 | 0 | For |
| ACUTA CAPITAL PARTNERS, LLC | 270,251 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 241,930 | 9,982 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 228,898 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 227,303 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 200,000 | 0 | 0 | 0 | For |
| BlackRock | 189,880 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 171,898 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 166,837 | 0 | 0 | 0 | For |
| Velan Capital Investment Management LP | 114,704 | 0 | 0 | 0 | For |
| Citadel | 111,254 | 0 | 0 | 0 | For |
| Vanguard | 106,098 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 103,626 | 0 | 0 | 0 | For |
| Renaissance | 70,169 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 61,828 | 0 | 0 | 0 | For |
| Two Sigma | 55,997 | 0 | 0 | 0 | For |
| Asset Management One Co., Ltd. | 35,295 | 0 | 0 | 0 | For |
| Northern Trust | 33,747 | 0 | 0 | 0 | For |
Institutional-manager reports, all 68 managers: 7,994,373 for, 11,507 against, 5,648 abstained. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Sutro Biopharma, Inc.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 13,893,289 for, 501 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,584,937 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 715,307 | 0 | 0 | 0 | For |
| Vanguard | 711,213 | 0 | 0 | 0 | For |
| Fidelity | 137,227 | 0 | 0 | 0 | For |
| Charles Schwab | 10,500 | 0 | 0 | 0 | For |
| Goldman Sachs | 4,092 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 3,000 | 0 | 0 | 0 | For |
| Equitable | 1,480 | 0 | 0 | 0 | For |
| BlackRock | 820 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 770 | 0 | 0 | 0 | For |
| Invesco | 179 | 0 | 0 | 0 | For |
| John Hancock | 153 | 0 | 0 | 0 | For |
| Northern Trust | 152 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 44 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 16,570,439 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | MUTUAL FUND SERIES TRUST | 4.32% |
| 2 | Vanguard | 4.29% |
| 3 | Fidelity | 0.83% |
| 4 | Charles Schwab | 0.06% |
| 5 | Goldman Sachs | 0.02% |
| 6 | BRIDGEWAY FUNDS INC | 0.02% |
| 7 | Equitable | <0.01% |
| 8 | BlackRock | <0.01% |
| 9 | Blackstone Alternative Investment Funds | <0.01% |
| 10 | Invesco | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BVF INC/IL | 7.55% |
| 2 | Affinity Asset Advisors, LLC | 6.32% |
| 3 | PERCEPTIVE ADVISORS LLC | 4.31% |
| 4 | Point72 | 3.97% |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 3.97% |
| 6 | Woodline Partners LP | 2.80% |
| 7 | Samsara BioCapital, LLC | 2.53% |
| 8 | ADAR1 Capital Management, LLC | 1.84% |
| 9 | ACUTA CAPITAL PARTNERS, LLC | 1.63% |
| 10 | ACADIAN ASSET MANAGEMENT LLC | 1.52% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Perceptive Advisors LLC | 7.87% | 13G |
| Affiliates of Biotechnology Value Fund LP | 7.55% | DEF14A |
| BVF PARTNERS L P/IL | 7.55% | 13G |
| Affinity Asset Advisors, LLC | 6.45% | 13G |
| Srinivas Akkaraju | 6.41% | 13G |
| Point72 | 4.18% | 13F |
| Vanguard Group | 2.27% | 13F |
| Point72 Asset Management, L.P. | 1.44% | 13G |
| BlackRock | 1.40% | 13F |
| Millennium Management | 1.27% | 13F |
Percentages above are of 16,570,439 shares outstanding, as reported by Sutro Biopharma, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Sutro Biopharma, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Sutro Biopharma, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “Sutro Biopharma (STRO) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/sutro-biopharma-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.